Home / Health / Research shows promising development in the hunt for an HIV vaccine.

Research shows promising development in the hunt for an HIV vaccine.

Although they are successful But the experiment is still in its early stages.

After more than 30 years of trying, there may be advances in the search for a vaccine for HIV, the virus that causes AIDS, if left untreated.

Now, preliminary data from the first phase of clinical trials from The International AIDS Vaccine Initiative and The Scripps Research Institute in La Jolla, California, suggest that a new HIV vaccine may hold promise.

“These were early studies but even provocative,”

; said Dr. William Schaffner, professor of preventive and infectious medicine at Vanderbilt University in Nashville, who did not. Related to clinical trials said

Although vaccinated participants will still need to be tested in larger studies. But experts are hopeful the vaccine might be successful in case others have failed.

“This is a new approach to vaccine development that has not been done before,” said Schaffner, describing the underlying vaccine technology as “a radical vaccine.” “The best of science in the 21st century”

When HIV was first found to be the cause of AIDS in the early 1980s, researchers thought a vaccine for the virus could be built up as quickly as for diseases such as measles, chickenpox and hepatitis B in In fact, the US Secretary at the time. In health and human services, Margaret Heckler predicted in 1984 that the vaccine would be available in two years. Researchers soon found that there were more obstacles than initially thought.

New research by IAVI and Scripps aims to address these issues by developing a vaccine that helps the body make The researchers hope to stimulate a person’s immune system against HIV and a number of mutations.

This research is based on “Identifying a subgroup of HIV-infected people … which, during infection, performs what is known as broad-spectrum neutral antibodies, in which these antibodies can generally prevent HIV infection at There is a variety. Variables, and that’s the key goal, ”says Dr. Mark Feinberg, Ph.D., CEO of IAVI.

Their initial phase 1 clinical trial, still pending, involved 48 healthy adults who received the vaccine or placebo, all two, two months apart. Initial data showed that 97% of people who received the vaccine had preliminary evidence that their immune systems might be able to make these broad-spectrum antibodies.

“Broadly neutral antibodies are important because viruses can mutate so quickly that they need something that is a shotgun, not a rifle … to protect against all sorts of HIV configurations,” Schaffner said. Said

The decades-long search for an HIV vaccine is in stark contrast to the development of a vaccine against COVID-19. “Where science is ready and we can develop a variety of vaccines very quickly,” Schaffner Add more

Researchers from IAVI and Scripps are partnering with companies such as Moderna to harness the mRNA technology used in the development of the COVID-19 vaccine.

Sara Yumeen, MD, is a primary year doctor at Hartford Healthcare St. Vincent Medical Center in Connecticut and is a supporter of the ABC News medical unit.

Source link